109: AB126, Exosomes, and Cerebroprotection for Stroke

NeurologyLive® Mind Moments®

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Stephen From, chief executive officer of Aruna Bio, sat down to discuss the company's investigational exosome candidate AB126 and its upcoming phase 1b/2a trial in patients with ischemic stroke. He discussed the mechanism of action of the therapy, the advantages of its anti-inflammatory and neuroprotective properties, and how it will be used with other stroke treatments. Furthermore, he gave insight on the complexities with conducting stroke trials and improving neurodegeneration in poststroke patients.
Looking for more stroke discussion? Check out the NeurologyLive® stroke clinical focus page.
Episode Breakdown:

• 1:00 – Overviewing phase 1b/2a trial
• 7:05 – Mechanism of action of AB126
• 11:15 – Neurology News Minute
• 13:45 – Role of AB126 in stroke treatment landscape
• 17:50 – Challenges with repairing neurodegeneration in stroke

This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• European Commission Approves Omaveloxolone as First Therapy for Friedreich Ataxia

• AVP-786 Falls Short in Phase 3 Study of Alzheimer Disease Agitation

• FDA Grants Priority Review to Efficacy Supplement for Sarepta Therapeutics’ SRP-9001 Indication Expansion

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.